1-20 of 34
Andrew A. Lane, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Giovanni Martinelli, MD, Elisabetta Todisco, MDPhD, Andrew A Lane, MD PhD, Evelyn Acuña-Cruz, MD, Eric Deconinck, MDPhD, Eunice S. Wang, MD, Kendra L. Sweet, MD MS, David A Rizzieri, MD, Luca Mazzarella, MDPhD, Daniel J. DeAngelo, MD PhD, Pau Montesinos, MD PhD, Corrado Tarella, Harry P. Erba, MD PhD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Callum M Sloss, PhD, Kara E Malcolm, RN, Patrick A Zweidler-McKay, MDPhD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–13.
https://doi.org/10.1182/blood-2020-139903
Published: 2020
Journal Articles

Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

Katsuhiro Togami, MDPhD, Sun Sook Chung, PhD, Vikas Madan, PhD, Christopher M. Kenyon, BS, Lucia Cabal-Hierro, PhD, Justin Taylor, MD, Sunhee Kim, MD, Gabriel K Griffin, MD, Mahmoud Ghandi, Jia Li, PhD, Yvonne Y. Li, PhD, Fanny Angelot-Delletre, PhD, Sabeha Biichle, Michael Seiler, Silvia Buonamici, PhD, Scott B Lovitch, MDPhD, Abner Louissaint, Jr., MD PhD, Elizabeth A Morgan, MD, Fabrice Jardin, MD PhD, Pier Paolo Piccaluga, MD PhD, David M. Weinstock, MD, Peter S. Hammerman, MD PhD, Henry Yang, PhD, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Francine Garnache-Ottou, PhD, Omar Abdel-Wahab, MD, H. Phillip Koeffler, MD, Andrew A Lane, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-137727
Published: 2020
Journal Articles

Single Cell RNA-Seq Reveals Deranged Developmental Hierarchy with Coexisting Oncogenic States and Immune Evasion Programs in ETP T-ALL

Amy Guillaumet-Adkins, PhD, Praveen Anand, PhD, Huiyoung Yun, PhD, Yotam Drier, PhD, Anna Rogers, Madhu M. Ouseph, Monica S. Nair, Sayalee Potdar, Randi Isenhart, Jake A. Kloeber, Tushara Vijaykumar, Guangwu Guo, Julia Frede, PhD MPhil, Marian H. Harris, MD PhD, Lewis B. Silverman, MD, Andrew A. Lane, MD PhD, Daniel J. DeAngelo, MD, Jon C. Aster, MD PhD, Bradley E. Bernstein, MD PhD, Jens G. Lohr, MD PhD, Birgit Knoechel, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3953.
https://doi.org/10.1182/blood-2019-130482
Published: 2019
Journal Articles

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Tianyu Cai, PhD, Kathryn L Black, PhD, Ammar S. Naqvi, PhD, Deanne Taylor, PhD, Ming Zhao, MD, Qi Yuan, Mayumi Sugita, MD, Roman Galetto, PhD, Agnès Gouble, PhD, Julianne N. P. Smith, PhD, Antonio Cavazos, Lina Han, PhD, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Helen Ma, MS, Sergej Konoplev, Guilin Tang, MD, Jun Gu, MD PhD, Xiaoping Su, PhD, Sattva S Neelapu, MD, Andrew A. Lane, MD PhD, Hagop M. Kantarjian, MD, Monica L. Guzman, PhD, Naveen Pemmaraju, MD, Andrei Thomas-Tikhonenko, PhD, Marina Y Konopleva, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2659.
https://doi.org/10.1182/blood-2019-126869
Published: 2019
Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naval G. Daver, MD, Pau Montesinos, MD PhD, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Nikolaos Papadantonakis, MDPhDMSc, Eric Deconinck, MD PhD, Harry P. Erba, MD PhD, Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, David A. Rizzieri, MD, Kendra L. Sweet, MD, Giovanni Martinelli, Corrado Tarella, MD, Elisabetta Todisco, MD PhD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, PhD, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 734.
https://doi.org/10.1182/blood-2019-128648
Published: 2019
Journal Articles

Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities

Rahul S. Vedula, MD, Marlise R. Luskin, MD, Kevin Copson, MA, Priti Kumari, M.S., Anne Charles, BS, Annette S. Kim, MD PhD, Elizabeth A Morgan, MD, Gregory A. Abel, MD MPH, Richard M. Stone, MD, Andrew A. Lane, MD PhD, R. Coleman Lindsley, MD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1819.
https://doi.org/10.1182/blood-2018-99-118746
Published: 2018
Journal Articles

Single-Cell RNA-Seq Reveals AML Cellular Hierarchies Relevant to Clinical Outcomes and Immunity

Peter Van Galen, PhD, Volker Hovestadt, PhD, Marc Wadsworth II, Travis Hughes, Gabriel Kenneth Griffin, MD, Julia A. Verga, Jason Stephansky, Timothy J. Pastika, Jennifer Lombardi Story, Geraldine S. Pinkus, MD, Olga Pozdnyakova, MD PhD, Ilene Galinsky, Richard M. Stone, MD, Timothy A. Graubert, MD, Alex K. Shalek, PhD, Jon C. Aster, MD PhD, Andrew A. Lane, MD PhD, Bradley E. Bernstein, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 542.
https://doi.org/10.1182/blood-2018-99-113502
Published: 2018
Journal Articles

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Anthony S. Stein, MD, Sumithira Vasu, MD MBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Sharon Spence, Shay Shemesh, Christopher Brooks, PhD, Ivan Bergstein, MD, Janice Chen, PhD, Vanessa Dunn, Peter McDonald, John Mark Sloan, MD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Y. Konopleva, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 765.
https://doi.org/10.1182/blood-2018-99-118966
Published: 2018
Journal Articles

Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models

Qi Zhang, PhD, Tianyu Cai, PhD, Lina Han, PhD, Vinitha Mary Kuruvilla, Sharlene Adams, PhD, Sloss M Callum, Karine Harutyunyan, PhD, Andrew A. Lane, MD PhD, Yelena Kovtun, PhD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Patrick Zweider McKay, MD PhD, Marina Y. Konopleva, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3956.
https://doi.org/10.1182/blood-2018-99-116771
Published: 2018
Journal Articles

Developmental Ontogeny of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Revealed By Recurrent High Burden Clonal Hematopoiesis, Including in "Skin-Only" Disease

Gabriel K Griffin, MD, Katsuhiro Togami, MD PhD, Elizabeth A Morgan, MD, Andrew A. Lane, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2755.
https://doi.org/10.1182/blood-2018-99-119945
Published: 2018
Journal Articles

Nucleosome Binding Protein HMGN1 Promotes HSPC Competitive Advantage with Decreased Quiescence and Cooperates with AML Oncogenes to Block Differentiation and Increase Clonogenicity

Lucia Cabal-Hierro, PhD, Katsuhiro Togami, MD PhD, Kelly Higby, Andrew A. Lane, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2606.
https://doi.org/10.1182/blood-2018-99-119348
Published: 2018
Journal Articles

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Kendra L. Sweet, MD, Andrew A. Lane, MD PhD, Anthony S. Stein, MD, Sumithira Vasu, MDMBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Phyu Aung, MD, Danielle Shubert, Sharon Spence, Shay Shemesh, Janice Chen, PhD, Christopher Brooks, PhD, Ivan Bergstein, MD, Peter McDonald, Trishna Goswami, MD, John Mark Sloan, MD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1298.
https://doi.org/10.1182/blood.V130.Suppl_1.1298.1298
Published: 2017
Journal Articles

Spliceosome Mutations Are Associated with Frailty in Older Patients with Myeloid Malignancies

Marlise R. Luskin, MD, Angel M. Cronin, MS, Kevin Copson, MA, Wooram Jung, Martha Wadleigh, MD, Daniel J. DeAngelo, MD, David P. Steensma, MD, Jane Driver, MD MPH, Andrew A. Lane, MD PhD, R. Coleman Lindsley, MD PhD, Gregory A. Abel, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4276.
https://doi.org/10.1182/blood.V130.Suppl_1.4276.4276
Published: 2017
Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Eunice S. Wang, MD, William Donnellan, Roland B. Walter, MD PhD, Ioannis Mantzaris, MD, Michael B. Maris, MD, Dale L. Bixby, David A. Rizzieri, MD, Stefan Faderl, Madlen Malinowski, Naveen Pemmaraju, MD, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Ross Lindsay, PhD, Christopher Brooks, PhD, Trishna Goswami, MD, Richard M. Stone, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2583.
https://doi.org/10.1182/blood.V130.Suppl_1.2583.2583
Published: 2017
Journal Articles

Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Tianyu Cai, PhD, Roman Galetto, PhD, Agnès Gouble, PhD, Julianne Smith, PhD, Antonio Cavazos, MSc, Lina Han, PhD, Qi Zhang, PhD MD, Vinitha Mary Kuruvilla, Sergej Naumovich Konoplev, MD PhD, Sattva S. Neelapu, MD, Andrew A. Lane, MD PhD, Monica L. Guzman, PhD, Hagop M. Kantarjian, MD, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2625.
https://doi.org/10.1182/blood.V130.Suppl_1.2625.2625
Published: 2017
Journal Articles

Resistance to SL-401 in AML and BPDCN Is Associated with Loss of the Diphthamide Synthesis Pathway Enzyme DPH1 and Is Reversible By Azacitidine

Jason Stephansky, Katsuhiro Togami, MDPhD, Mahmoud Ghandi, PhD, Joan Montero, PhD, Nick vonEgypt, Ross Lindsay, PhD, Christopher Brooks, PhD, Jon C. Aster, MD PhD, Cory Johannessen, PhD, Andrew A. Lane, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 797.
https://doi.org/10.1182/blood.V130.Suppl_1.797.797
Published: 2017
Journal Articles

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Janice Chen, PhD, Shay Shemesh, MA, Peter McDonald, Christopher L. Brooks, PhD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2016) 128 (22): 342.
https://doi.org/10.1182/blood.V128.22.342.342
Published: 2016
Journal Articles

Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Tianyu Cai, PhD, Roman Galetto, PhD, Agnès Gouble, PhD, Julianne Smith, PhD, Antonio Cavazos, MS, Sergej Konoplev, MD PhD, Andrew A. Lane, MD PhD, Monica L. Guzman, PhD, Hagop M. Kantarjian, MD, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4039.
https://doi.org/10.1182/blood.V128.22.4039.4039
Published: 2016
Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax

Joan Montero, PhD, Jason Stephansky, BS, Tianyu Cai, PhD, Gabriel K. Griffin, MD, Katsuhiro Togami, MD PhD, Lucia Cabal-Hierro, PhD, Nicole R. LeBoeuf, MD, Leah Hogdal, PhD, Ilene Galinsky, MSN, ANPc, Jon C. Aster, MD PhD, Matthew S. Davids, Naveen Pemmaraju, MD, Richard M. Stone, MD, Marina Konopleva, MD PhD, Anthony Letai, MD PhD, Andrew A. Lane, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4045.
https://doi.org/10.1182/blood.V128.22.4045.4045
Published: 2016
Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Eunice S. Wang, MD, William B. Donnellan, MD, Roland B. Walter, MD PhD, Anthony S. Stein, MD, David A Rizzieri, MD, Hetty E. Carraway, MD MBA, Ioannis Mantzaris, MD, Thomas Prebet, MD PhD, Michael B. Maris, MD, Stefan Faderl, MD, Dale L. Bixby, MD PhD, Janice Chen, PhD, Ross Lindsay, PhD, Shay Shemesh, MA, Christopher L. Brooks, PhD, Richard M. Stone, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2016) 128 (22): 215.
https://doi.org/10.1182/blood.V128.22.215.215
Published: 2016